ISRCTN38082350已完成不适用
Dose-response study of 17DD yellow fever vaccine produced by Bio-Manguinhos/Fiocruz
Bio-Manguinhos/Fiocruz (Brazil)0 个研究点目标入组 1,050 人开始时间: 2008年12月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 1,050
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1. Adult men
- •2. Aged 18 - 30 years old
- •3. Healthy
- •4. Agree to participate after reading and understanding Free and Informed Consent Form
排除标准
- •1. Prior vaccination against yellow fever
- •3. Use of immunosuppressor drugs in the last 12 months
- •4. Personal history of autoimmune diseases
- •5. Personal history of thymus diseases
- •6. Personal history of anaphylactic reactions to foods, drugs or vaccines
- •7. Personal history of allergy to eggs, erythromycin, canamycin or gelatin
- •8. Persons who received immunoglobulin, blood transfusions or blood derivatives in the last 12 months
- •9. Persons who received live virus vaccines or cholera vaccine in the last 30 days or who plan to receive them in the following 30 days after yellow fever vaccination
研究者
相似试验
已完成
不适用
Yellow fever vaccine dose-response study on childreInfections and InfestationsYellow FeverYellow feverISRCTN36905484Bio-Manguinhos/Fiocruz (Brazil)1,800
进行中（未招募）
不适用
Study of Yellow Fever Vaccine Administered With Sanofi Pasteur's Dengue Vaccine in Healthy Toddlers at 12-13 Months of Age in Colombia and PeruPrevention of symptomatic dengue diseaseEUCTR2014-001714-26-Outside-EU/EEASanofi Pasteur SA792
进行中（未招募）
不适用
Immunity of the Vaccine against Yellow Fever in patients taking medications that affect the immune systemnspecified rheumatoid arthritisM06.9RBR-946bv5Centro de Pesquisas René Rachou- FIOCRUZ
已完成
不适用
Measurement of yellow fever vaccine efficacy; is 10 years the right point in time for revaccination?Yellow fever infection10047438NL-OMON39667Academisch Medisch Centrum119
尚未招募
不适用
Immunity induced by yellow fever vaccination in the elderly (60yrs or older)travellergele koorts, oudere, reizen, neutraliserende antistoffen, bijwerkingenyellow fever, elderly, travel, neutralizing antibodies, adverse eventsNL-OMON20831A.H.E. Roukens en L.G. Visser60